Navigation Links
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Date:9/3/2008

SB-509 to be Evaluated in Repeat-Dosing Study in Subjects with ALS

RICHMOND, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure.

Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). SB-509 is also in three additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown to have nerve protection properties as well as promoting nerve, blood vessel and muscle growth.

In ALS, the motor nerves comprised of nerve cells in the brain and spinal cord that control the body's voluntary muscles, gradually degenerate. As the nerve cells begin to die, the muscles weaken and shrink. As the disease progresses, patients gradually lose the use of their limb and neck muscles, ultimately becoming paralyzed and unable to breathe without assistance. Fifty percent of patients with ALS die within three to five years of diagnosis. Currently, there is only one approved drug for ALS; Riluzole has been demonstrated to slow the progression of this debilitating disease with only modest clinical benefit, extending the survival of ALS patients by approximately three months.

"Initiation of a Phase 2 clinical study of SB-509 in subjects with a motor neuron and muscle disease such as ALS is an obvious next step in the evaluation of this novel therapeut
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2009)...val of New Anti-TNF Therapy in Three Rheumatic Dis... HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PRNew...d Schering-Plough Corporation (NYSE: SGP ) annou...ts for Human Use (CHMP) of the European Medicines ...ing the approval of SIMPONI(TM) (golimumab) as a o...
(Date:6/25/2009)...ewswire/ -- As of mid-2009, The Michael J. Fox Fou...d over $1 million in high-risk, high-reward approa...h its groundbreaking Rapid Response Innovation Aw...ty and efficacy of an FDA-approved drug for kidney... a tenuous link between PD and certain strains of ...
(Date:6/25/2009)...ring ARIKACE for Once-Daily Treatment of Pseudomon... June 25 Cystic Fibrosis Foundatio...e Cystic Fibrosis Foundation, has provided a $2.2 ...development of ARIKACE(TM) (liposomal amikacin for...eudomonas lung infections in cystic fibrosis (CF)...
(Date:6/24/2009)...ire/ -- In a revolutionary healthcare finding, a p...sh Journal of Nutrition (a Cambridge University ... cholesterol and triglycerides, control body weigh...lled clinical study was conducted on rats and show...l rate to 24 months versus a 50% survival rate for...
Breaking Medicine Technology:SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 2MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33% 2Small Business Turns Out on Super Tuesday 11321 1Small Business Turns Out on Super Tuesday 11321 2Small Business Turns Out on Super Tuesday 11321 3Genome wide survey nets key melanoma gene 11316 1Genome wide survey nets key melanoma gene 11316 2Genome wide survey nets key melanoma gene 11316 3Genome wide survey nets key melanoma gene 11316 4Bone complications due to cystic fibrosis have a genetic cause according to an MUHC study 11315 1Torchmark Corporation to Present at Merrill Lynch Insurance Investors Conference 11310 1
(Date:7/2/2009)...entists at Singapore,s Bioprocessing Technology In...w the gene, "Fas-apoptosis inhibitory molecule" (F...optosis, or programmed cell death. , Their rese...th and Differentiation . , The scientists, Jianx...red that this process may possibly be manipulated ...
(Date:7/2/2009)...ORT MYERS, Fla., July 2 ...-the-counter and prescription medicines to help re... acetaminophen by a brand name, Tylenol and prescr...An advisory committee for the FDA met on June 30, ...use of acetaminophen. The committee voted 20-17 t...
(Date:7/2/2009)...exas Health one of 63 businesses honored in Washin...swire-USNewswire/ -- Texas Health Resources has ...s award from the National Business Group on Healt.../prnh/20090702/DC41773LOGO ) , , The award r...novative programs that promote a healthy workplace...
(Date:7/2/2009)... explores weight problems faced by youngsters with...hDay News) -- Children with type 1 diabetes are mo...disease, increasing their risk of serious health c... from a major study that explored the weight probl... a less common form of the disease that usually sh...
Breaking Medicine News(10 mins):Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3Health News:Kids With Type 1 Diabetes Often Overweight 2
...ional Institutes of Health, showed that at-risk pe...uced their risk of diabetes by 58%, even without m...pe 2 diabetes can sharply reduce the odds through ..., according to data from the nation's first major ...
...h zinc sulphate.Livogen Z is one of the three vers...gen was an old product of Glaxo India with Rs 3 cr...rand to E Merck India Ltd. According to a notific...ange (BSE), Glaxo India signed a memorandum of und...
Axert has been approved by the FDA for the acute treatment of migraine with or without aura in adults. This drug targets serotonin receptors and act against migraine headaches by inducing the constri
...ater may be the latest blood pressure drug for som...c Dysfunction Center reported that water has a pow...o experience fainting spells while standing.// Blo...within two or three minutes after the water was in...
Other Medicine News:
...oguide an physiological navigation system for neur...rising breakthrough for Micro electrode recording ...ion for the treatment of movement disorders in Par...y, thalamotomy and other similar neurosurgical pro...
...g advanced 3D matching algorithms developed by Med...althmerge automatically merges image sets from a v...dless of acquisition orientation. Stealthmerge eve...g the requirement to scan tissue outside the targe...
...ell Surgiplan is an advanced image-based neurosurg...Leksell Stereotactic System. Preoperative planning... It offers powerful functions to visualize and ana...erent surgical approaches. The unique tools for fu...
It provides cranial support in either supine or semi-sitting procedures.
Medicine Products: